Health experts say that while lenacapavir is a major advance in HIV prevention, the twice-yearly injectable drug does not ...

The CDC has updated its HIV testing guidance, emphasizing routine, opt-out screening for patients aged 13–64 and more frequent testing for those at higher risk. The approach aims to reduce stigma, ...

While the technique can be performed in low-resource settings, it’s time consuming and misses half or more of TB cases. Rapid ...

Ntungamo District is grappling with a growing dual public health challenge, with HIV/Aids prevalence rising to 6 percent--above the national average of 5.1 percent--alongside sustained transmission of ...

Introduction Postpartum disengagement from HIV care increases risks for adverse maternal health outcomes and transmission of ...

The injectable drug is administered once every six months and is being positioned as a convenient alternative to daily oral ...

Primary outcome measures The primary outcome was time to HIV care attrition, defined as death, discontinuation of ...

Len is a gamechanging drug to prevent HIV infections, priced by Gilead at $28,200. Limited drug is available at cost to low-income countries. Research ethics are discussed.

An increasing number of U.S. states have passed laws that allow health care providers – including doctors, nurses and pharmacists – to refuse to treat patients based on their personal or religious ...

In a new NIH-funded Johns Hopkins Medicine study, researchers used a computer model to quantify the effect of funding cuts for HIV testing. They estimate that HIV infections could increase an average ...

Timely HIV diagnosis and treatment are critical to preventing transmission. To help make this happen, the U.S. Centers for Disease Control and Prevention (CDC) provides funding for HIV testing to ...